Digital Trials Digest, our quarterly newsletter
Expectations for the time it takes to complete a vaccine clinical trial have been radically raised by the mRNA vaccines’ successes.
Decentralized trials (DCTs) expand older adults’ access to trials, allowing them to participate at higher rates.
Digital transformation is reshaping nearly every industry, and clinical trials are no exception. As technology plays a bigger role in healthcare, patients are demanding more access to medical research. It’s not just patients who are asking for more: Medical professionals, researchers, and pharmaceutical companies all want to improve quality, efficiency, and access to clinical trials.
The use of real world data in clinical trials is a hot topic. Doctors, biotech and pharmaceutical companies alike point to the tremendous potential to leverage this data to improve health outcomes.
Virtual clinical trials aren’t just a buzzword—these research models are here to stay. In fact, the global market for virtual clinical trials is expected to reach $12.9 billion by 2030, according to Grand View Research.
When it comes to clinical trials, DCT and digital therapeutic (DTx) companies are natural partners. Both are tech savvy and adept in digital health
Decentralized clinical trials offer an effective avenue to mitigate the issues that typify pediatric clinical trials, including patient-reported data accuracy.
Though incidences of pneumonia have decreased overall, the disease is the leading infectious cause of death in children globally, affecting 1 in 6 child deaths.
In our conversations with trial sponsors, ObvioHealth often tackles common misconceptions about decentralized clinical trials (DCTs). These myths hinder our industry’s evolution by keeping sponsors from designing optimal trials that deliver better data with higher retention and compliance rates.